Download PDF
Thromb Haemost 1996; 76(06): 0925-0931
DOI: 10.1055/s-0038-1650687
Original Article
Schattauer GmbH Stuttgart

Immunologic Assessment of Patients Treated with Bovine Fibrin as a Hemostatic Agent

John F Carroll
1   The Department of Biochemistry, Temple University School of Medicine, Philadelphia
,
Keith A Moskowitz
1   The Department of Biochemistry, Temple University School of Medicine, Philadelphia
,
Niloo M Edwards
2   Division of Cardiothoracic Surgery, College of Physicians and Surgeons, Columbia University, New York, USA
,
Thomas J Hickey
2   Division of Cardiothoracic Surgery, College of Physicians and Surgeons, Columbia University, New York, USA
,
Eric A Rose
2   Division of Cardiothoracic Surgery, College of Physicians and Surgeons, Columbia University, New York, USA
,
Andrei Z Budzynski
1   The Department of Biochemistry, Temple University School of Medicine, Philadelphia
› Author Affiliations
Further Information

Publication History

Received 09 January 1996

Accepted after resubmission 03 September 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Twenty-one cardiothoracic surgical patients have been treated with fibrin as a topical hemostatic/sealing agent, prepared from bovine fibrinogen clotted with bovine thrombin. Serum samples have been collected before treatment with fibrin and postoperatively between 1 and 9 days, 3 and 12 weeks, and 6 and 8 months. The titers of anti-bovine fibrinogen antibodies, measured by ELISA specific for immunoglobulins IgG or IgM, increased to maximal values after about 8 or 6 weeks, respectively. After 8 months, IgG titers were on average 20-fold lower than the mean maximal value, while IgM titers returned to the normal range. IgG was the predominant anti-bovine fibrinogen immunoglobulin as documented by ELISA, affinity chromatography and electrophoresis. Anti-bovine fibrinogen antibodies present in patients reacted readily with bovine fibrinogen, but did not cross-react with human fibrinogen as measured by ELISA or by immunoelectrophoresis. A significant amount of antibodies against bovine thrombin and factor V has been found, many cross-reacting with the human counterparts. No hemorrhagic or thrombotic complications, or clinically significant allergic reactions, occurred in any patient, in spite of antibody presence against some bovine and human coagulation factors. The treatment of patients with bovine fibrin, without induction of immunologic response against human fibrinogen, appeared to be an effective topical hemostatic/sealing measure.

 

  • References

  • 1 Bergel S. Über Wirkung des Fibrins. Deutsch Med Wchschrft 1909; 35: 663
    PubMedGoogle Scholar
  • 2 Grey EG. Fibrin as a haemostatic in cerebral surgery. Surg Gynecol Obstet 1915; 21: 452-454
    PubMedGoogle Scholar
  • 3 Harvey SC. The use of fibrin paper and forms in surgery. Boston Med Surg J 1916; 174: 658-659
    CrossrefPubMedGoogle Scholar
  • 4 Gerendas M. Fibrin products as aids in hemostasis and wound healing. In: Fibrinogen Laki K. ed. Marcel Dekker, Inc; New York, NY: 1968: 277-316
  • 5 Gibble JW, Ness PM. Fibrin glue: the perfect operative sealant?. Transfusion 1990; 30: 741-747
    CrossrefPubMedGoogle Scholar
  • 6 Kang SS, Gosselin C, Ren D, Greisler HP. Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by fibroblast growth factor-1 plus heparin delivered from fibrin glue suspensions. Surgery 1995; 118: 280-287
    CrossrefPubMedGoogle Scholar
  • 7 Tanemoto K, Fujinami H. Experimental study on bacterial colonization of fibrin glue and its prevention. Clinical Therapeutics 1994; 16: 1016-1027
    PubMedGoogle Scholar
  • 8 Strieker RB, Lane PK, Leffert JD, Rodgers GM, Shuman MA, Corash L. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 1988; 72: 1375-1380
    PubMedGoogle Scholar
  • 9 Zehnder JL, Leung LLK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-2016
    PubMedGoogle Scholar
  • 10 Budzynski AZ, Marder VJ, Parker ME, Shames P, Brizuela BS, Olexa SA. Antigenic markers on fragment DD, a unique plasmic derivative of human crosslinked fibrin. Blood 1979; 54: 794-804
    PubMedGoogle Scholar
  • 11 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 12 Clausen J. Immunochemical techniques for the determination and estimation of macromolecules. North-Holland Publ Co; Amsterdam, The Netherlands: 1971: 454-465
  • 13 Engvall E. Enzyme immunoassay ELISA and EMIT. Meth Enzymol 1980; 70: 419-439
    PubMedGoogle Scholar
  • 14 Heene DL, Matthias FR. Adsorption of fibrinogen derivatives on insolubilized fibrinogen and fibrin monomer. Thromb Res 1973; 2: 137-154
    CrossrefPubMedGoogle Scholar
  • 15 Pandya BV, Gabriel JL, O’Brien J, Budzynski AZ. Polymerization site in the β chain of fibrin: Mapping of the Bβ1-55 sequence. Biochemistry 1991; 30: 162-168
    CrossrefPubMedGoogle Scholar
  • 16 Fowler WE, Erickson HP. Trinodular structure of fibrinogen. Confirmation by both shadowing and negative stain electron microscopy. J Mol Biol 1979; 134: 241-249
    CrossrefPubMedGoogle Scholar
  • 17 Williams RC. Morphology of bovine fibrinogen monomers and fibrin oligomers. J Mol Biol 1981; 150: 399-408
    CrossrefPubMedGoogle Scholar
  • 18 Prowse CV, Hornsey V, Ruckley CV, Boulton FE. A comparison of acylated streptokinase-plasminogen complex and streptokinase in healthy volunteers. Thromb Haemost 1982; 47: 132-135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Ellis SG, Tcheng JE, Navetta FI, Muller DW, Weisman HF, Smith C, Anderson KM, Califf RM, Topol EJ. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Art Dis 1993; 4: 167-175
    CrossrefPubMedGoogle Scholar
  • 20 Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: A mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989; 111: 631-634
    CrossrefPubMedGoogle Scholar
  • 21 Diez-Martin J, Sikkink RA, Gilchrist GS, Bowie EJW, Fass DN. Development of anti-bovine thrombin antibodies following neurosurgical procedures. Br J Haematol 1990; 74: 369-370
    CrossrefPubMedGoogle Scholar
  • 22 Lawson JH, Pennell BJ, Olson JD, Mann KG. Isolation and characterization of an acquired antithrombin antibody. Blood 1990; 76: 2249-2257
    PubMedGoogle Scholar
  • 23 Rapaport SI, Zivelin A, Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Amer J Clin Pathol 1992; 97: 84-91
    PubMedGoogle Scholar
  • 24 Berruyer M, Amiral J, French P, Belleville J, Bastien O, Clerc J, Kassir A, Estanove S, Dechavanne M. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. J Thorac Cardiovasc Surg 1993; 105: 892-897
    PubMedGoogle Scholar
  • 25 Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. J Neurosurg 1993; 78: 817-820
    CrossrefPubMedGoogle Scholar
  • 26 Banninger H, Hardegger T, Tolber A, Barth A, Schupbach P, Reinhart W, Lammle B, Furlan M. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Brit J Haematol 1993; 85: 528-532
    PubMedGoogle Scholar
  • 27 Milde LN. An anaphylactic reaction to fibrin glue. Anesth Analg 1989; 69: 684-686
    PubMedGoogle Scholar
  • 28 Berguer R, Staerkel RL, Moore EE, Moore FA, Galloway WB, Mockus MB. Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. J Trauma 1991; 31: 408-411
    CrossrefPubMedGoogle Scholar
  • 29 Tadokoro K, Ohtoshi T, Takafuji S, Nakajima K, Suzuki S, Yamamoto K, Ito K, Miyamoto K, Muranaka M. Topical thrombin-induced IgE-mediated anaphylaxis: RAST analysis and skin test studies. J Allergy Clin Immunol 1991; 88: 620-629
    CrossrefPubMedGoogle Scholar
  • 30 Doolittle RF. Structural aspects of the fibrinogen to fibrin conversion. Adv Prot Chem 1973; 27: 1-109
    PubMedGoogle Scholar
  • 31 Sierra DH. Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. J Biomat Appl 1993; 7: 309-352
    CrossrefPubMedGoogle Scholar
  • 32 Spotnitz WD. Fibrin sealant in the United States: clinical use at the University of Virginia. Thromb Haemost 1995; 74: 482-485
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Martinowitz U, Schulman S. Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Thromb Haemost 1995; 74: 486-492
    Article in Thieme ConnectPubMedGoogle Scholar